Mel Roca, MD
Family Medicine · Council Bluffs, IANPI 1841427564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 765 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 765 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- Aimmune Therapeutics, Inc.$777
- Pfizer$751
- Amgen$738
- plus $6K from 51 others
What the payments were for
- Speaking & faculty fees$5004%
- Food & beverage$12,64996%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,192 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 129 | $104,572 |
| FarxigaDapagliflozin Propanediol | 95 | $94,483 |
| MounjaroTirzepatide | 75 | $81,104 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $80,608 |
| JardianceEmpagliflozin | 63 | $80,105 |
| OzempicSemaglutide | 54 | $69,053 |
| TrulicityDulaglutide | 40 | $67,603 |
| MyrbetriqMirabegron | 36 | $33,669 |
| KerendiaFinerenone | 34 | $29,790 |
| XareltoRivaroxaban | 26 | $25,582 |
| LinzessLinaclotide | 29 | $20,523 |
| QuliptaAtogepant | 16 | $17,197 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $16,117 |
| RybelsusSemaglutide | 14 | $15,321 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $12,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $669 | $148,707115 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $1,279 | $118,160140 claims |
| PfizerEliquis | $751 | $104,572129 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $627 | $96,725116 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $1,154 | $88,60979 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $301 | $85,16574 claims |
| AbbVieLinzess, Qulipta, Restasis | $2,463 | $45,55158 claims |
| Astellas Pharma US IncMyrbetriq | $223 | $33,66936 claims |
| BayerKerendia | $610 | $29,79034 claims |
| Johnson & JohnsonXarelto | $268 | $25,58226 claims |
| MerckJanuvia | $68 | $9,74419 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $90 | $8,72918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Council Bluffs
- Kevin SheppardCouncil Bluffs$20K
- Kavish RohatgiCouncil Bluffs$14K
- Joseph WanzekCouncil Bluffs$13K
- James WhalenCouncil Bluffs$11K
- Barclay MonasterCouncil Bluffs$10K
- Krista HillCouncil Bluffs$8K
- Jamie ArmbrusterCouncil Bluffs$7K
- Thomas McElderryCouncil Bluffs$7K
- Pranith SurabhiCouncil Bluffs$7K
- Christian JonesCouncil Bluffs$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.